Article Text

Download PDFPDF
Letter in response to ‘Coagulation and fibrosis in chronic liver disease’
  1. K Borensztajn1,
  2. M P Peppelenbosch2,
  3. C A Spek1
  1. 1
    Center for Experimental and Molecular Medicine, Academic Medical Center, Amsterdam, The Netherlands
  2. 2
    Cell Biology and Immunology, University of Groningen, Groningen, The Netherlands
  1. Correspondence to Dr K Borensztajn, Center for Experimental and Molecular Medicine G2-106, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands; k.s.borensztajn{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We read with interest the paper by Calvaruso and colleagues discussing the role of coagulation in fibrosis in chronic liver disease.1 Fibrotic diseases, and especially liver fibrosis, are a major public health issue, and remain too often refractory to therapy. Novel treatment options are therefore eagerly awaited. Overall, we agree with the author’s conclusions that compelling evidence supports a close relationship between thrombin and hepatic fibrogenesis and that targeting the coagulation cascade might be an attractive therapeutic avenue for the management of liver fibrosis. This notion is underscored by the fact that anticoagulant therapy already showed promise in idiopathic pulmonary fibrosis where it improved overall survival.2

Although we would …

View Full Text


  • Competing interests None.

  • Provenance and Peer review Not commissioned; not externally peer reviewed.